AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11092283
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus metformin
Trial: 9321764
Drug: Isoniazid as
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid as probe drug
Trial: 8462143
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg sublingual GTN
Trial: 29370143
Drug: CHO-REPLACE (15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-REPLACE (15% carbohydrate solution; 221.4 ± 59.3 g maltodextrin)
Trial: 29370143
Drug: CHO-DEFICIT (non-caloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-DEFICIT (non-caloric artificially-sweetened placebo solution)
Trial: 23254579
Drug: High-dose ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ARB (n = 22)
Trial: 15845509
Drug: Vibrio cholerae
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrio cholerae 638 vaccine (10^9 CFU buffered with 1.3% NaHCO3)
Trial: 15845509
Drug: Vibrio cholerae
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrio cholerae 638 vaccine
Trial: 10355070
Drug: Sotalol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (2 x 160 mg)
Trial: 10355070
Drug: Quinidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine + Verapamil (3 x 160 mg + 3 x 80 mg)
Trial: 20022206
Drug: Perioperative β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative β-blockers
Trial: 18971181
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of nalmefene (2 mg)
Trial: 18971181
Drug: Multiple intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravenous doses of nalmefene (2 mg once daily for 6 days)
Trial: 12801736
Drug: Multiple-dose activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose activated charcoal (50 g every 6 hours for 3 days)
Trial: 12801736
Drug: Multiple-dose activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose activated charcoal
Trial: 11192146
Drug: Rivastigmine 6
RxNorm normalized name: rivastigmine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 6 to 12 mg/d
Trial: 2862297
Drug: Oral triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral triazolam 0.5 mg
Trial: 29527973
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention (barbers encouraged meetings with specialty-trained pharmacists who prescribed drug therapy)
Trial: 25214778
Drug: Indacaterol 75
RxNorm normalized name: INDACATEROL 75MCG CAP,INHL,30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 75 μg
Trial: 1695304
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg b.i.d.
Trial: 366145
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro levamisole added to lymphocyte culture prior to drug treatment
Trial: 25736164
Drug: Siltuximab 11
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 11 mg/kg every 3 weeks
Trial: 21272712
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy plus physical therapy (MET plus PT)
Trial: 10228117
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP; 250 microgram twice a day)
Trial: 10228117
Drug: Salbutamol (Sb;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (Sb; 400 microgram twice a day)
Trial: 8912948
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of meta-chlorophenylpiperazine (MCPP) at a dose of 0.06 mg/kg
Trial: 24798350
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg) combined with methotrexate (MTX) therapy, administered at weeks 0, 2, 6, and 14.
Trial: 24798350
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy (Control group).
Trial: 23789705
Drug: T100 PARI
RxNorm normalized name: PARIS QUADRIFOLIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T100 PARI (150 mg/1.5 mL) nebulized with a PARI eFlow nebulizer
Trial: 23789705
Drug: TOBI (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOBI (300 mg/5 mL) nebulized with a PARI LC PLUS nebulizer
Trial: 16685253
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) 40 to 60 mg orally
Trial: 15078394
Drug: Prophylactic advisory
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic advisory device replacement recommended for prior appropriate ICD therapy
Trial: 7798068
Drug: Indapamide 1.25
RxNorm normalized name: indapamide 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.25 mg once daily for 8 weeks
Trial: 7798068
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg once daily for 8 weeks
Trial: 7798068
Drug: Indapamide 1.25
RxNorm normalized name: indapamide 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.25 mg
Trial: 2750695
Drug: Tryptophan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (3 g)
Trial: 2750695
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g lactose)
Trial: 776880
Drug: 5% methenamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% methenamine in a firm stick gel, applied daily to one palmar or plantar surface
Trial: 22169724
Drug: Three stages
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three stages of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT)
Trial: 17431366
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of prulifloxacin (600 mg) before the operation
Trial: 11717015
Drug: Aprotinin (10(6)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (10(6) kallikrein inhibitory units (KIU) loading dose followed by the same dose during chest closure)
Trial: 9219164
Drug: Fosinopril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril, 10 mg by mouth daily (treated group)
Trial: 2972054
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (240 micrograms, 40 micrograms each nostril, repeated twice at 15 min intervals)
Trial: 27206914
Drug: 25% PAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% PAA treatment
Trial: 27206914
Drug: 17% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17% EDTA treatment
Trial: 18523440
Drug: 1.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/day plant sterols in margarine divided equally at each of the three daily meals (three times per day)
Trial: 18523440
Drug: 1.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/day plant sterols in margarine with breakfast (single-BF)
Trial: 9799203
Drug: Oral methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine load (0.1 g/kg)
Trial: 9345462
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon beta-1a (IFN-beta-1a) 6.0 x 10(6) IU (30 micrograms) administered by weekly intramuscular injections
Trial: 24953046
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy with rosuvastatin
Trial: 24953046
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with pravastatin
Trial: 15746633
Drug: Aspirin administration
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin administration before surgery
Trial: 15746633
Drug: Non-aspirin (control)
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin (control) group
Trial: 9808219
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg RRR-alpha-tocopheryl acetate
Trial: 1266422
Drug: D(‐)penicillamine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D(‐)penicillamine (900 mg) plus salicylate (1500 mg)
Trial: 1266422
Drug: Prednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (10 mg) plus salicylate (1500 mg)
Trial: 28432468
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous acetaminophen administered over 15, 60, or 120 minutes
Trial: 25545331
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (600 mg/d ubiquinol) with simvastatin 20 mg/d
Trial: 25545331
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with simvastatin 20 mg/d
Trial: 18628521
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone administration (T(4) 50 microg and T(3) 0.67 microg/kg.d)
Trial: 16950363
Drug: Chaperonin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaperonin 10 (5 mg)
Trial: 16950363
Drug: Chaperonin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaperonin 10 (7.5 mg)
Trial: 16950363
Drug: Chaperonin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaperonin 10 (10 mg)
Trial: 16950363
Drug: Chaperonin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaperonin 10 (all doses)
Trial: 8942005
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin injection using buffered regular insulin
Trial: 8942005
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin injection using unbuffered regular insulin
Trial: 8942005
Drug: Isophane insulin
RxNorm normalized name: Isophane insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isophane insulin injected at bedtime
Trial: 1723684
Drug: Urinary trypsin
RxNorm normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary trypsin inhibitor for 3 days postoperatively
Trial: 1723684
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no therapeutic agent)
Trial: 1723684
Drug: Urinary trypsin
RxNorm normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary trypsin inhibitor
Trial: 7041937
Drug: Bendrofluazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (5 mg a day)
Trial: 7041937
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of indapamide and bendrofluazide
Trial: 29462248
Drug: Non-platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-based chemotherapy (NPBC)
Trial: 18258988
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy based on pretreatment clinical extent of disease and pathologic extent after chemotherapy
Trial: 9481995
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg/night)
Trial: 9481995
Drug: Placebo (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25 mg/night)
Trial: 3371084
Drug: Frusemide/amiloride (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide/amiloride (40 mg frusemide plus 5 mg amiloride per tablet)
Trial: 3371084
Drug: Bumetanide/potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide/potassium chloride (0.5 mg bumetanide plus 573 mg slow‐release potassium chloride per tablet)
Trial: 30201040
Drug: Baby Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby Triple P Positive Parenting Programme plus treatment as usual (TAU)
Trial: 26816607
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day duloxetine
Trial: 24331628
Drug: TACE combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE combined with iodine [131I] metuximab injection
Trial: 24331628
Drug: TACE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE therapy alone (Control Group)
Trial: 20147334
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (good PS)
Trial: 20147334
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (poor PS)
Trial: 16632815
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron (1 mg)
Trial: 9793287
Drug: Fluconazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (50 mg daily for 14 days)
Trial: 9793287
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg daily for 15 days)
Trial: 2518679
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (NGO, 18 mg)
Trial: 6758932
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg tiapamil intravenously
Trial: 30969142
Drug: Lower sodium
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower sodium chloride diet (6 g/d)
Trial: 30969142
Drug: Higher sodium
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher sodium chloride diet (12 g/d)
Trial: 29368069
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with red, 655-nm laser light, 150 mW, 2 J/cm2, on days 0, 3, 5, and 7
Trial: 19546072
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg/day orally for 2 weeks before surgery)
Trial: 17635062
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic and fluid resuscitation (Control)
Trial: 15726917
Drug: Estradiol (1
RxNorm normalized name: fluoroestradiol (18F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (1 mg oral)
Trial: 12046257
Drug: Effervescent tablet
RxNorm normalized name: Pain Relief Effervescent Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablet (Calcium 500 mg Pharmavit)
Trial: 12046257
Drug: Milk (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (250 ml enriched with milk calcium complex)
Trial: 9468366
Drug: ZDV 200
RxNorm normalized name: ZDV
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZDV 200 mg three times daily plus p24‐VLP (500 microg) in intramuscular alum monthly
Trial: 9468366
Drug: ZDV 200
RxNorm normalized name: ZDV
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZDV 200 mg three times daily plus intramuscular administration of alum adjuvant monthly
Trial: 9468366
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules plus p24‐VLP (500 microg) in intramuscular alum monthly
Trial: 7589843
Drug: Increased fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased fasting insulin (quartile 4, high)
Trial: 7589843
Drug: Increased fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased fasting insulin and decreased delta I30/delta G30
Trial: 2202010
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion for 12 hours during arteriography
Trial: 2202010
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during arteriography
Trial: 28041700
Drug: Telmisartan 80mg
RxNorm normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 80mg once daily for six months
Trial: 28041700
Drug: Enalapril 20mg
RxNorm normalized name: enalapril 20 MG
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 20mg once daily for six months
Trial: 21562072
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (wP, 80 mg/m(2)/week)
Trial: 21562072
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + carboplatin (wP + C, AUC 5 mg/ml/min every 4 weeks)
Trial: 21562072
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + topotecan (wP + wT, 3 mg/m(2)/week)
Trial: 21562072
Drug: Control (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (monotherapy vs combination therapy)
Trial: 11862589
Drug: Basiliximab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (40 mg, two 20 mg bolus injections on days 0 and 4)
Trial: 11862589
Drug: Basiliximab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (40 mg)
Trial: 10215945
Drug: Malmö Treatment
RxNorm normalized name: Salmo masoni flesh
DrugBank: Rainbow trout (DB15540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malmö Treatment Model protocol including immunoadsorption, cyclophosphamide (12-15 mg/kg bw intravenously for 2 days, then 2-3 mg/kg bw orally for 8-10 days), and intravenous gammaglobulin (0.4 g/kg bw daily for 5 days)
Trial: 10215945
Drug: Malmö Treatment
RxNorm normalized name: Salmo masoni flesh
DrugBank: Rainbow trout (DB15540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malmö Treatment Model protocol
Trial: 7611753
Drug: AO‐90 amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU and MMC
Trial: 7611753
Drug: Amiparen (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU and MMC
Trial: 7611753
Drug: AO‐90 amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU for 7 days
Trial: 7611753
Drug: Amiparen (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU for 7 days
Trial: 80632
Drug: Ancrod (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ancrod (5 daily subcutaneous injections)
Trial: 31999405
Drug: Hijamat (wet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hijamat (wet cupping therapy) plus standard lifestyle modification
Trial: 22971205
Drug: Pharmacist-led pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led pharmaceutical care intervention program
Trial: 15125352
Drug: Esmolol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 150 mcg/kg
Trial: 15125352
Drug: Nicardipine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 15 mcg/kg
Trial: 15125352
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg/kg
Trial: 9928562
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CT) and reduced-dose radiation therapy (RT)
Trial: 9928562
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CT) and full-dose radiation therapy (RT)
Trial: 9928562
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy starting with chemotherapy (CT)
Trial: 9928562
Drug: Initiating radiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initiating radiation therapy (RT) sooner
Trial: 9928562
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment regimens delivering CT in a short time period (Adriamycin and Cytoxan in four 3-week cycles)
Trial: 3300561
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: metoclopramide and droperidol (2.5 mg i.v. every 8 h X 3)
Trial: 30032828
Drug: Escalated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated therapy (B) with radiation dose up to 84 Gy